Capromab Biosimilar – Anti-FOLH2 mAb – Research Grade

Description of Capromab Biosimilar - Anti-FOLH2 mAb - Research Grade

Introduction to Capromab Biosimilar – Anti-FOLH2 mAb

Capromab Biosimilar, also known as Anti-FOLH2 monoclonal antibody (mAb), is a research grade antibody that has gained significant attention in the field of cancer therapy. This antibody is designed to target the folate hydrolase 2 (FOLH2) protein, which is overexpressed in various types of cancer, making it a promising therapeutic target. In this article, we will discuss the structure, activity, and potential applications of Capromab Biosimilar – Anti-FOLH2 mAb.

Structure of Capromab Biosimilar – Anti-FOLH2 mAb

Capromab Biosimilar is a recombinant humanized monoclonal antibody that is derived from a mouse hybridoma cell line. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the FOLH2 protein, while the constant region determines the effector functions of the antibody.

Binding to FOLH2 protein

The FOLH2 protein is a transmembrane glycoprotein that is highly expressed on the surface of cancer cells, particularly in prostate, bladder, and ovarian cancers. It plays a crucial role in tumor growth and progression, making it an attractive target for cancer therapy. Capromab Biosimilar binds to the extracellular domain of FOLH2 with high specificity and affinity, allowing for targeted delivery of therapeutic agents to cancer cells.

Effector functions of Capromab Biosimilar

Apart from its ability to bind to the FOLH2 protein, Capromab Biosimilar also possesses effector functions that contribute to its anti- cancer activity. These include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). These functions involve the activation of immune cells, such as natural killer cells and macrophages, to directly kill cancer cells.

Activity of Capromab Biosimilar – Anti-FOLH2 mAb

The primary activity of Capromab Biosimilar is to inhibit the growth and proliferation of cancer cells by targeting the FOLH2 protein. This antibody has been shown to induce cell death in FOLH2-expressing cancer cells, both in vitro and in vivo. Additionally, its effector functions also contribute to its anti- cancer activity by enhancing the immune response against cancer cells.

Potential Applications of Capromab Biosimilar – Anti-FOLH2 mAb

Capromab Biosimilar has the potential to be used in various applications, including cancer diagnosis, imaging, and therapy. Its high specificity for the FOLH2 protein makes it a valuable tool for detecting and imaging FOLH2-expressing tumors. In fact, a radiolabeled version of this antibody, known as ProstaScint, has been approved by the FDA for imaging prostate cancer. Furthermore, Capromab Biosimilar can also be used as a therapeutic agent for cancer treatment, either alone or in combination with other anti- cancer drugs.

Cancer diagnosis and imaging

As mentioned, Capromab Biosimilar can be used for cancer diagnosis and imaging by targeting the FOLH2 protein. This antibody can be labeled with a radioactive isotope, such as technetium-99m, and injected into the patient. The radiolabeled antibody will then bind to FOLH2-expressing tumors, allowing for accurate detection and localization of cancer cells.

Cancer therapy

Capromab Biosimilar can also be used as a therapeutic agent for cancer treatment. Its ability to specifically target and kill FOLH2-expressing cancer cells makes it a promising candidate for targeted therapy. Additionally, its effector functions can enhance the immune response against cancer cells, making it a potential immunotherapy agent.